Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | NQO2 | P16083 | 1/20 | 0.50 |
| ▸ | ESR1 | P03372 | 1/20 | 0.46 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | PDE10A | Q9Y233 | 5/20 | 0.45 |
| ▸ | CYSLTR1 | Q9Y271 | 2/20 | 0.45 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.45 |
| ▸ | NCF1 | P14598 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3267444 | 0.84 | CYSLTR1 (0.57) | CYP1A2ALDH1A1PDE10ACYSLTR1CYSLTR2 | |
| SCHEMBL30879956 | 0.84 | CYSLTR1 (0.57) | CYP1A2ALDH1A1PDE10ACYSLTR1CYSLTR2 | |
| SCHEMBL4938792 | 0.82 | CYSLTR1 (0.55) | CYP1A2ALDH1A1PDE10ACYSLTR1CYSLTR2 | |
| SCHEMBL19130544 | 0.82 | CYP1A2 (0.49) | CYP1A2ALDH1A1PDE10ACYSLTR1CYSLTR2 | |
| SCHEMBL6681790 | 0.79 | NQO2 (0.65) | CYP1A2ALDH1A1NQO2ESR1CYP2A6 | |
| Hydrochloric Acid SCHEMBL29033530 | 0.77 | NQO2 (0.63) | CYP1A2ALDH1A1NQO2ESR1CYP2A6 | |
| SCHEMBL16284370 | 0.77 | CYP1A2 (0.57) | CYP1A2ALDH1A1NQO2ESR1CYP2A6 | |
| Iodide SCHEMBL27917416 | 0.77 | NQO2 (0.63) | CYP1A2ALDH1A1NQO2ESR1CYP2A6 | |
| Iodide SCHEMBL1353852 | 0.77 | NQO2 (0.63) | CYP1A2ALDH1A1NQO2ESR1CYP2A6 | |
| SCHEMBL6586916 | 0.76 | KMT2A (0.56) | CYP1A2ALDH1A1NQO2ESR1CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200048223-A1 | WNT SIGNALING PATHWAY INHIBITORS AND THERAPEUTIC APPLICATIONS THEREOF | Suzhou Yunxuan Yiyao Keji Youxian Gongsi (CN) | 2020-02-13 | — | — | US | disclosed |
| US-10450300-B2 | Wnt signaling pathway inhibitors and therapeutic applications thereof | Suzhou Yunxuan Yiyao Keji Youxian Gongsi (CN) | 2019-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10450300-B2 | Wnt signaling pathway inhibitors and therapeutic applications thereof | WNT1, WNT3A, CTNNB1 | CYP1A2 2852/4885ALDH1A1 1909/4885NQO2 2684/4885 |
| US-20200048223-A1 | WNT SIGNALING PATHWAY INHIBITORS AND THERAPEUTIC APPLICATIONS THEREOF | WNT1, WNT3A, CTNNB1 | CYP1A2 2852/4885ALDH1A1 1909/4885NQO2 2684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.